223 drugs out of Gansu market (list attached)

On the 15th, Gansu Province's centralized procurement network for pharmaceutical and medical supplies issued a document "on the state-organized centralized procurement of drugs related to drug price adjustment related matters notice.", Gansu Province announced that the state-organized centralized procurement of drugs with the common name of the same product regulations to further adjust prices, to guide drug production enterprises to return to rational and quality competitionresults have now been announcedThe announcement shows that the provincial public resources transaction signed the relevant drug price adjustment declaration acceptance and data summary work, by the provincial drug and medical supplies centralized procurement of the office of the joint meeting of the leadership group study decision, is now 584 drug price declaration data and the proposed processing opinions for publicity (excluding 184 drugs have been included in the settlement and monitoring system)After the expiration of the publicity period, the complaint will be divided into batchesSeiber Blue combed found that a total of 223 drugs have been removed from the net, because it is not rated has been linked to the net drugs, and the price is higher than the evaluation grid, the variety of over-rated enterprises more than 3in response to this problem, Jiangsu Province Pharmaceutical Co, Ltdretail purchasing manager Jia Xiaoqing said to Seiberblue: for 223 pharmaceutical manufacturers, the cancellation of the network qualification means the loss of market share, the loss of the loss for enterprises is unbearablein addition,, 182 drugs have been suspended, of which 13 were selected for Gansu's listed net drugs, which did not meet the difference in price; The price difference is more than 2 times, not according to the required gradient price reduction, there are 31 unrated has been linked to the net drugs, the price is higher than the evaluation grid, over the evaluation has not been 3;January 17, the national centralized procurement of drugs produced the results of the proposed selection, the collection of 33 varieties of 32 successful procurement, a total of 100 products selected122 enterprises participated, resulting in the selection of 77 enterprisesCompared with the 2018 minimum purchase price in the Alliance region, the average price of the proposed winning stakes fell by 53%, with the highest reduction reaching 93%This centralized procurement, comparing international prices with domestic prices, overall in line with expectationswith the implementation of the results of the national collection, the fate of the corresponding varieties has become a matter of concernon the, the substitution effect of the selected varieties on the unselected varieties is obviousTaking the results of the implementation of the 4 plus 7 as an example, the data show that the overall sales share of the brand that imitated the winning brand increased from 14.5% in April 2018 to 44.5% in April 2019, while the overall sales share of the original non-winning bid decreased from 45.6% in the same period33.1%, the overall sales share of the imitation did not win the bid in the same period from 35.6% to 17.8%on the other hand, many provinces issued documents, requiring the unselected varieties ladder price reduction, if the price is not in place, the cancellation of the network, as in Gansu Provincethis, Jia Xiaoqing think: This is not surprising, since the country to speed up the promotion of the varieties, then we must give a certain advantage of the varieties, the so-called advantage is the threshold, the priority principle of the reviewer, so that enterprises have the incentive to spend costs to do consistent evaluationFrom the 2012 "National Drug Safety" 12th Five-Year Plan put forward the evaluation node to now, the speed is obviously too slowin fact, since the launch of the purchase of the 4 plus 7 band volume, the relevant varieties in the sector has been inevitable price reduction - all over the deployment of unselected drugs gradient price reduction work, according to incomplete statistics, Beijing, Shanghai, Tianjin, Shaanxi, Shanxi, Hainan, Heilongjiang and other places have launched the non-selected drug gradient price reductionnow with the national harvest gradually landing, and normal, the non-selected varieties failed to reduce prices in accordance with the provisions, will face the problem of exiting the marketin addition, for pharmaceutical companies, if not over the consistency of evaluation, price reduction can only temporarily retain the market, with their own variety consistency evaluation full of three, will eventually suspend the network, facing a greater risk of survival, although in the short term can also operate in the non-standard market, but with the gradual landing of the results of the band procurement, the future operating market will be less and lesscurrently through and as if through the consistency of the evaluation of a total of 846 drugs, involving a total of 404 product regulations, of which 82 product regulations have been evaluated enterprises have reached threebut there are some varieties have been rated a lot, but there has been a "one-place chicken hair" situationAmong them, the number of benzene sulfonate chlorpyrifos (5mg) has been evaluated by 28 manufacturers, metformin hydrochloride tablets (0.25g) have 21 manufacturers have been consistent evaluation, in the burden of evaluation costs at the same time, the competition is further intensifiedso, is the consistency evaluation done or not?Jia Xiaoqing believes that: consistency evaluation is the future of pharmaceutical production enterprises must do, in 2012 the National Drug Safety "12th Five-Year Plan" proposed "to improve the quality of generic drugs in an all-round way", for generic drugs through consistency made a time node, such as the norms pointed out" Incorporated into the national list of essential drugs, clinically commonly used generic drugs completed by 2015, did not pass the quality consistency evaluation of non-registration, write off their drug approval documents", although in the process of landing some of the difficulties of implementation, but consistency evaluation must be the future trendhe further explained that, indeed, many single-products have been rated more, leading to increased competition, which raises a problem: the days of previously relying on reviews for an advantage have disappearedHowever, evaluation elimination, over-review still face fierce competition, then, enterprises should look for core competitiveness, for too many single products, if the enterprise does not have a strong competitive strength, suggest to give up the evaluation, put energy into other single products, choose a new product breakthrough from the national level of national collection, to explore regional-level band procurement, to the local departments concerned to guide the unselected drug ladder price reduction, the national pharmaceutical industry "low-cost tide" to come have research institutions said: over-rated varieties have been more than 200, consistency evaluation constraints basically eliminated, the future collection of land-to-landing speed is expected to accelerate , sample hospital Top100 best-selling drugs, and have rated manufacturers will be a large probability into the band procurement According to the Health Insurance Agency, best-selling varieties are more likely to be included in band purchases Non-Top100 best-selling drugs, but have reviewed manufacturers may also be included in the band purchase enterprises should evaluate their own product positioning, as early as possible to make trade-offs with 223 list of de-registered drugs: